Abstract 953P
Background
Second-line treatment options for patients with unresectable hepatocellular carcinoma (uHCC) are limited. Monotherapy with regorafenib or tislelizumab (an anti-PD-1 antibody) has shown clinical benefit for uHCC in the second-line setting. The present study explored the safety and efficacy of the tislelizumab plus regorafenib as second-line therapy for uHCC.
Methods
This was a single-arm, investigator-initiated phase II trial. Patients with confirmed uHCC were enrolled to receive tislelizumab (200mg, q3w) plus regorafenib (80mg-160mg, daily, 3 weeks on/1 week off, every 4 weeks). The primary endpoint was safety and tolerability; Secondary endpoints included overall response rates (ORR), progression-free survival (PFS), and disease control rate (DCR) per mRECIST.
Results
A total of 28 patients were enrolled with median age of 59 years (range: 40-76) and 96% were men. Most common etiology of HCC was hepatitis B (n=26, 93%). 54% of patients were Barcelona Clinic Liver Cancer stage C. 67.9% of patients received prior treatment with tyrosine kinase inhibitors (TKIs; sorafenib [50%] or lenvatinib [17.9%]), and 21.4% received TKIs plus PD-1 antibody. ORR was 28.6% and DCR was 71.4%, with 3 pts having CR, 5 PR, and 12 SD. At the data cut-off date, the median PFS of the 28 pts was 6.4 months (95%Cl 90%, NA)), and the median OS was not reached. The most common treatment-related adverse events at any grade were rash (6/28;21%), hypertension (9/28;32%), hand-foot syndrome (18/28;64%) and fatigue (7/28;25%), which were mostly grade 1 or 2 in severity.
Conclusions
This study indicated that tislelizumab plus regorafenib is an effective and well-tolerated therapeutic option for patients with uHCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Xuetao Shi.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
990P - Prognosis prediction for unresectable hepatocellular carcinoma undergoing hepatic arterial infusion chemotherapy using convolutional neural network model
Presenter: bing quan
Session: Poster session 18
991P - Real-world comparison of trans-arterial chemoembolization and bland embolization for the treatment of hepatocellular carcinoma: A propensity score analysis
Presenter: Allan Ramos-Esquivel
Session: Poster session 18
993P - Thyroid dysfunction after atezolizumab and bevacizumab is associated with favorable outcomes in hepatocellular carcinoma (IMbrave150 and Korean patients cohorts)
Presenter: Hongjae Chon
Session: Poster session 18
995P - Real-world treatment patterns, survival and costs in advanced hepatocellular carcinoma (aHCC) in Ontario, Canada
Presenter: Dominick Bossé
Session: Poster session 18
996P - Transarterial chemoembolization combined donafenib with/without programmed death-1 inhibitors for initially unresectable hepatocellular carcinoma in a multicenter retrospective study
Presenter: Xuhua Duan
Session: Poster session 18
998P - Efficacy and safety of curative hepatectomy after conversion therapies for initial unresectable hepatocellular carcinoma: A multicenter propensity score matching study
Presenter: Rong-yun Mai
Session: Poster session 18